This inventor holds 1 USPTO granted patent and 3 published patent applications and 1 EPO patent. Top assignee: Convergent R.n.r Ltd.. Active years: 2019.
Company Filing History:
Years Active: 2019
Title: Miri Markovich: Innovator in Targeted X-Ray Therapy
Introduction
Miri Markovich is a prominent inventor based in Haifa, Israel. She has made significant contributions to the field of medical technology, particularly in the area of targeted x-ray therapy. Her innovative approach aims to enhance the effectiveness of drug activation in vivo, providing new avenues for treatment.
Latest Patents
Miri Markovich holds a patent for a groundbreaking invention titled "Means and methods for targeted x-ray therapy." This patent outlines a method for activating a pro-drug within a subject's body. The process involves administering a pro-drug, locating a target site that has been dosed with the pro-drug, and exposing that site to x-ray radiation. The x-ray exposure is designed to be highly controlled, ensuring that the dosage at the target site is sufficient to convert the pro-drug into an active drug, while minimizing exposure to adjacent non-target sites. This innovative method has the potential to significantly improve therapeutic outcomes.
Career Highlights
Throughout her career, Miri has demonstrated a commitment to advancing medical technology. She is currently associated with Convergent R.N.R Ltd., where she continues to develop her ideas and contribute to the field. Her work has garnered attention for its potential to revolutionize treatment methodologies.
Collaborations
Miri collaborates with notable colleagues, including Zeev Harel and Zeev Burshtein. These partnerships enhance her research and development efforts, fostering an environment of innovation and creativity.
Conclusion
Miri Markovich is a trailblazer in the realm of targeted x-ray therapy, with a patent that showcases her innovative spirit and dedication to improving medical treatments. Her contributions are paving the way for future advancements in the field.